Csl Limited

Genentech, Inc.

Medimmune Limited

Walter and Eliza Hall Institute of Medical Research

Zenyth Operations Pty. Ltd.

The University of Queensland

Viela Bio, Inc.

Merck + Co., Inc.

Yale University

Manuel Baca

Andrew Donald Nash

Louis Jerry Fabri

James A Wells

Zhiqiang An

William Strohl

Dennis M Zaller

Leonard G Presta

Henry Bernard Lowman

Nicos Anthony Nicola

Yvonne Man-Yee Chen

Felicity Meredith Dunlop

Douglas James Hilton

Ronald Herbst

Sandra Elaine Nicholson

Jeffrey S Swers

Stacey Drabic

Thomas Thisted

Herren Wu

Anthony Coyle

Con Panousis

Perry Francis Bartlett

Matthew Hardy

Kirsten Edwards

Vaheh Oganesyan

David Kenneth Spencer

Luba Grinberg

Shabazz Novarra

Trevor Kilpatrick

Arna Elizabeth Andrews

Benoy Chacko

Elizabeth Jane Coulson

Andrew C Nyborg

Katrina Fieldew

Cheema Surindar

Richard John Simpson

Donald Metcalf

Jack A Elias

Tracy Ann Willson

David Tice

Warren S Alexander

Raymond Stanley Norton

Jian Guo Zhang

Jian-Guo Zhang

Alison Farley

William R Strohl

Pierre David Scotney

Jeffrey James Babon

Edward James McManus

Shenggen Yao

Peter Emtage

Kirsten Mae Edwards

Matthew Philip Hardy

The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein

The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer

Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.

Uricase sequences and methods of treatment

Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).

CD40L-Fc fusion polypeptides and methods of use thereof

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R&#x3b1;1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R&#x3b1;1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R&#x3b1;1-mediated activities are also disclosed.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

CD40L-specific TN3-derived scaffolds and methods of use thereof

The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.

TRAIL R2-specific multimeric scaffolds

Antibodies against G-CSFR and uses thereof

The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.

Protein scaffolds

The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.

Method of treating cancer comprising a VEGF-B antagonist

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R&#x3b1;1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R&#x3b1;1-mediated activities are also disclosed.

Anti-IL-13R&#x3b1;1 antibodies and their uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Manuel Baca